| Date | Title | | | 12/12/07 | Genoptix Reports Strong Financial Results For Third Quarter 2007| 134% Increase In Revenues Year-Over-Year
CARLSBAD, Calif., Dec. 12 /PRNewswire-FirstCall/ -- Genoptix, Inc.
(Nasdaq: GXDX), a specialized laboratory service provider, today reported
revenues of $16.2 million for the third quarter ended September 30, 2007, an
increase of 134% over revenues of $6.9 million for the comparable period in
2006. For the nine months ended September 30, 2007, the Company reported
revenues of $40.8 million, an increase of 152% over revenues of... |
|  | | 12/07/07 | Genoptix, Inc. Announces Availability of MPL W515 L/K Mutation Analysis for MPD at 49th Annual American Society of Hematology (ASH) Meeting|
SAN DIEGO, Dec. 7 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX),
a provider of personalized diagnostic services, announced today at the ASH Meeting
in Atlanta, Georgia, that it will launch testing for the MPL W515 L/K mutation.
This new test further expands the Genoptix service offering for patients with
hematomalignancies, or cancers of the blood, to improve diagnosis and management.
Genoptix believes it will be the first commercial hematology/oncology laborator... |
| | | 11/28/07 | Genoptix, Inc., to Announce Third Quarter 2007 Financial Results and Host Conference Call and Webcast on December 12, 2007| SAN DIEGO--(BUSINESS WIRE)--Nov. 28, 2007--Genoptix, Inc.
(NASDAQ:GXDX), a provider of personalized diagnostic services,
announced today that it expects to report its unaudited financial
results for the third quarter 2007 after the NASDAQ Global Market
closes on Wednesday, December 12, 2007. The press release will be
available shortly thereafter through the investor relations section of
the Genoptix website at www.genoptix.com.
A conference call will take place on the same day, We... |
| | | 11/02/07 | Genoptix, Inc. Announces Closing of IPO and Exercise in Full of Underwriters' Over-Allotment Option | SAN DIEGO, Nov. 2 /PRNewswire/ -- Genoptix, Inc. announced today that
it has closed its previously announced initial public offering of 5,000,000
shares and that the underwriters of the offering have exercised in full
their 30-day option to purchase an additional 750,000 shares of common
stock, which includes 450,000 shares sold by Genoptix and 300,000 shares
sold by certain selling stockholders. The purchase price of the shares was
$17.00 per share. Genoptix sold a total of 4,735,714 ... |
| | | 10/29/07 | Genoptix, Inc. Announces Pricing for Initial Public Offering| SAN DIEGO, Oct 29, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Genoptix, Inc. announced
today the pricing of its initial public offering of 5,000,000 shares of common
stock at a price of $17.00 per share. 4,285,714 shares are being offered by
Genoptix and 714,286 shares are being offered by certain selling stockholders.
In addition, Genoptix and the selling stockholders have granted to the
underwriters a 30-day option to purchase up to an additional 750,000 shares of
common stoc... |
| |
|
